Back to Authors

Sharman, Jeffrey P.

A5023212171 | I4210148213

Mayo Clinic

Willamette Valley Cancer Institute and Research Center

Citations 3

99 | FIXED DURATION SUBCUTANEOUS MOSUNETUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM THE PHASE II MORNINGSUN STUDY

Hematological Oncology | June 17, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_99

P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1043-1044

10.1097/01.hs9.0000847492.88194.df

INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.63_2879